Tiny Health Raises $33M Series B Led by B Capital to Scale Microbiome Testing Platform

Tiny Health Secures $33 Million Series B

Tiny Health, an Austin, Texas-based microbiome testing platform, has raised $33 million in Series B funding. The round was led by B Capital and included participation from Gaingels, Overwater Ventures, Black Opal Ventures, Spero Ventures, Alumni Ventures, Denver Ventures, Pave Health Ventures, TheVentureCity, and Pari Passu Venture Partners. The funding date is September 29, 2026.

What Tiny Health Does

Tiny Health offers at-home gut and vaginal microbiome tests spanning pregnancy, infancy, and adulthood. Its tests use shotgun metagenomic sequencing to detect microbes across more than 120,000 genomes at strain level. All testing is processed in CLIA-certified labs. Results are paired with science-backed action plans to help users understand and act on their microbiome data.

Founded in 2020 by Cheryl Sew Hoy, the company has served nearly 200,000 customers and more than 6,000 healthcare practitioners. Its offerings include consumer tests and a B2B platform called Powered by Tiny, which grew 4x in the past year. Enterprise partners include Fullscript, Mayo Clinic Executive Health and Longevity Programs, and Superpower.

Why It Matters

The microbiome testing market is expanding as consumers and healthcare providers seek more personalized health insights. Tiny Health's strain-level sequencing and CLIA-certified lab processing provide a differentiated technical foundation. The company's dual consumer and B2B approach allows it to capture value across both direct-to-consumer and enterprise channels.

Acquisition Angle

For acquirers, Tiny Health represents a scaled microbiome testing platform with a growing B2B business. The Powered by Tiny platform, with its 4x growth and notable enterprise partners, could be attractive to diagnostic companies, health systems, or wellness platforms looking to integrate microbiome data into their offerings. The company's extensive customer base and practitioner network also provide a ready-made distribution channel.

Key Facts

• Company: Tiny Health
• Headquarters: Austin, Texas
• Founded: 2020
• Founder: Cheryl Sew Hoy
• Business: At-home gut and vaginal microbiome testing for pregnancy, infancy, and adulthood
• Technology: Shotgun metagenomic sequencing detecting microbes across more than 120,000 genomes at strain level
• Lab certification: CLIA-certified labs
• Customers served: Nearly 200,000
• Healthcare practitioners served: More than 6,000
• B2B platform: Powered by Tiny, grew 4x in the past year
• Enterprise partners: Fullscript, Mayo Clinic Executive Health and Longevity Programs, Superpower
• Round: Series B
• Amount: $33 million
• Lead investor: B Capital
• Other investors: Gaingels, Overwater Ventures, Black Opal Ventures, Spero Ventures, Alumni Ventures, Denver Ventures, Pave Health Ventures, TheVentureCity, Pari Passu Venture Partners
• Funding date: September 29, 2026

Outlook

With $33 million in new capital, Tiny Health is well-positioned to expand its microbiome testing platform, grow its B2B partnerships, and reach more consumers and practitioners. The involvement of B Capital and a broad investor syndicate underscores confidence in the company's technology and market opportunity.